Key points are not available for this paper at this time.
The sharing of pathogen samples and their associated genetic sequence data (GSD) is crucial for global pandemic prevention, preparedness and response. It enables global surveillance, risk assessment and the research and development of pandemic-related products. The sharing of related benefits is also seen as key to ensuring more equitable global access to the fruits of science. These issues, collectively known as Pathogen Access and Benefit Sharing (PABS), remain a major point of contention in the ongoing Pandemic Agreement negotiations. In this post, I explore potential scenarios regarding the establishment or absence of the new PABS System, and their implications under international law.
Adam Strobeyko (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: